SAGE-718

Sage Therapeutics' focus is on developing compounds that are positive allosteric modulators (PAM) of both synaptic and extrasynaptic sites of either the GABA receptor or the NMDA receptor system.
The companies second area of focus is on the NMDA receptor with SAGE-718. SAGE-217 targets the GABA receptor, SAGE-718 targets the NMDA receptor. The company is currently in phase 1 testing with oral drug SAGE-718.
The unique position the company finds itself in, is unlike SAGE-217 which primarily targets depression, SAGE-718 will target different indications with zero overlap. Within NMDA hypofunction the company is targeting indications such as Huntington’s, ADHD, and Alzheimer’s disease, potentially creating another very large revenue stream in the future. The company has SAGE-904 which also target’s the NMDA receptor and is in pre-clinical studies.

The patent for SAGE-718 from the company’s 10K below.

We also own twenty families of applications directed to modulators of NMDA receptors. Fifteen of these families of patent applications are directed to compounds that modulate NMDA receptors, including SAGE-718, which can be used to treat NMDA receptor-related disorders such as CNS-related conditions. One of these families of patent applications is directed to using a naturally occurring compound as a biomarker for a subject who would benefit from treatment with a modulator of NMDA receptors. One of these families of patent applications is directed to using a modulator of NMDA receptors to treat a rare NMDA loss of function disorder. Any patents that may issue, if any, from these families of applications directed to modulators of NMDA receptors would have statutory expiration dates in September 2032 and October 2037.